

Table 23: One-, Two-, Three-, Four-, Five-, and 10-Year Relative Survival Rates^{a,b} For Selected Malignant Brain and Central Nervous System Tumors, SEER 17 Registries, 1995-2006

Histology	# Cases	1-Yr	2-Yr	3-Yr	4-Yr	5-Yr	10-Yr
Pilocytic astrocytoma	2,064	97.76%	96.69%	95.64%	94.69%	94.04%	91.43%
Protoplasmic & fibrillary astrocytoma	554	74.60%	60.51%	54.99%	50.93%	47.43%	35.49%
Anaplastic astrocytoma	2,599	59.78%	42.28%	34.50%	30.34%	27.42%	21.31%
Astrocytoma, NOS	3,011	69.29%	59.12%	53.65%	50.05%	47.54%	38.67%
Glioblastoma	17,672	33.67%	11.89%	6.82%	5.08%	4.46%	2.70%
Oligodendroglioma	2,236	94.11%	89.82%	86.36%	82.58%	79.05%	64.22%
Anaplastic oligodendroglioma	906	79.31%	65.22%	58.96%	52.60%	47.42%	34.83%
Ependymoma/anaplastic ependymoma	1,569	93.92%	88.81%	85.28%	82.70%	81.86%	76.74%
Mixed glioma	1,135	87.00%	74.61%	67.09%	61.39%	56.97%	45.80%
Glioma malignant, NOS	2,492	59.03%	47.66%	44.68%	42.66%	41.47%	38.29%
Neuroepithelial	97	55.54%	43.46%	42.47%	37.65%	33.63%	27.53%
Malignant neuronal/glia, Neuronal and mixed	480	88.60%	79.43%	76.15%	70.71%	69.48%	57.59%
Embryonal/primitive/medulloblastoma	1,671	82.39%	71.81%	66.67%	63.44%	61.36%	54.28%
Lymphoma	3,116	47.38%	37.94%	33.27%	30.02%	27.46%	20.45%
Total: All Brain and CNS^c	42,866	56.70%	42.86%	38.62%	36.39%	35.10%	31.50%

^aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

^bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.

^cIncludes histologies not listed in this table.

Abbreviations: SEER, Survival, Epidemiology and End Results; NOS, not otherwise specified.